NCT03709641View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effectiveness of Restylane-Defyne for Punctual Occlusion

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

November 28, 2018

Study Completion Date

November 28, 2018

Conditions
Mild to Moderate Dry Eye Disease
Interventions
DEVICE

Restylane Defyne

Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL

Trial Locations (1)

40206

The Eye Care Institute, Louisville

All Listed Sponsors
lead

John C Meyer, MD

OTHER

NCT03709641 - A Study to Evaluate the Safety and Effectiveness of Restylane-Defyne for Punctual Occlusion | Biotech Hunter | Biotech Hunter